Sichuan Biokin Pharmaceutical News

Dongwu Securities released a research report on April 11 stating that it gave Bailey Tianheng (688506.SH) a purchase rating. The main reasons for the rating include: 1) traditional formulations nurture innovation, paving the way for Baili Tianheng; 2) BL-

Zhitong FinanceApr 11 18:12

Bailey Tianheng-U (688506): pioneered dual-antibody ADC to write a new chapter in global blockbuster products

東吳證券Apr 11 06:11

Bailey Tianheng-U (688506) Important Review: FIC varieties that have received a down payment of 800 million US dollars from BMS are expected to deliver on global value

華創證券Mar 12 23:02

Bailey Tianheng (688506): Increased R&D to accelerate the globalization of B01D1

廣發證券Mar 2 10:00

Baili Tianheng (688506) 2023 annual performance forecast review: R&D investment increased year-on-year, product value continued to be realized

東北證券Jan 29 10:00

Baili Tianheng (688506): B01D1 accelerates the globalization process of overseas licensing

廣發證券Dec 20, 2023 10:00

Bailey Tianheng (688506): B01D1 global development is progressing rapidly

廣發證券Aug 29, 2023 11:00

Bailey Tianheng (688506): Preliminary nasopharyngeal cancer data are excellent and may add new indications

廣發證券Mar 12, 2023 18:33

Bailey Tianheng-U (688506): Potential global giant variety B01D1 with multiple differentiated research projects

廣發證券Jan 30, 2023 00:11

Bailey Tianheng (688506) IPO Coverage Study

華金證券Dec 18, 2022 10:00